General Catalyst’s Customer Value Fund (CVF) provides late-stage companies with a balance sheet for growth. CVF pre-funds companies’ sales and marketing and is paid back by a capped share of the ...

Vitalhub Corp. (TSX: VHI) (OTCQX: VHIBF) (the “Company” or “VitalHub”) announced that it has completed the cash acquisition of Induction Healthcare Group PLC (“Induction”) by way of a court-sanctioned ...

Nusano will supply dGenThera with At-211 in quantities sufficient to enable the company’s ongoing preclinical studies, first‑in‑human trials, and subsequent clinical development. The agreement ...

About Katie Ledecky Katie Ledecky is a nine-time Olympic gold medalist and 21-time world champion swimmer. Katie is a strong ...

Founded by a team of world-renowned academics from the Universities of Oxford and Cambridge and seasoned life sciences entrepreneurs, Symbiotic.blue is currently raising a pre-seed round to build its ...

Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced an exclusive partnership with Grow Sciences, a cultivator of ...

Accèdez sans limite aux 15 000 actualités du site et recevez gratuitement chaque semaine, la Newsletter Santé log avec les ...

AMSTERDAM, Netherlands, June 19, 2025 (GLOBE NEWSWIRE) -- HLTH Inc., the leading global platform for health innovation, is proud to announce the launch of HLTH.rad, a groundbreaking new event that ...

Per June 16, 2025, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,532,753 shares, corresponding to 5.02% (previously 4.85%) of the total share capital attached to shares.

Virbac annonce la nomination de Paul Martingell en tant que directeur général du groupe Virbac à compter du 1er septembre 2025.

The CancerVax platform is designed to harness the body’s existing immunity to detect, mark, and kill cancer cells with precision. At the core of the platform are nanoparticles that operate via a ...

AVMAPKI™ FAKZYNJA™ CO-PACK is approved for the treatment of adult patients with KRAS -mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. IBTROZI™ is ...